TAMPA, Fla. — The Food and Drug Administration has granted accelerated approval to the experimental drug lecanemab, shown to slow down the progression of Alzheimer’s disease in its early stages.

Read full-text medical journal articles from Medscape's Pharmacists News.

AAIC 2025 Lecanemab Preserves Memory Over 4 Years in Early AD Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a ...